Skip to main content

Posts

Showing posts with the label progressive multifocal leukoencephalopathy

New risk factor for leukoencephalopathy Progressive multifocal (PML) associated with Tysabri (natalizumab)

The Food and Drug Administration (FDA) and inform the public that have been identified to test positive for antibodies against JC (JCV) as a risk factor for HIV leukoencephalopathy progressive multifocal (PML).  PML is an inflammation of the brain are rare but serious associated with use of Tysabri (natalizumab) for the treatment of multiple sclerosis (MS) or Crohn's disease. It should be that the risks and benefits of continuing treatment with Tysabri be carefully considered in patients who are found to be anti-JCV antibodies of the positive and you have one or more of the other risk factors known to the PML.  Patients who suffer from all the three known risk factors have estimated the risk of PML of 11/1 for users, 000.  Risk factors are: The presence of antibodies against JCV. Longer duration of treatment Tysabri, especially after 2 years. Before treatment with immunosuppressive drugs (for example, mitoxantrone, azathioprine, methotrexate, cyclophosphamide, or inhibition mofet